Compare Stocks: GANX, FATE, SABS, and MYGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.60 +1.2%	$2.48	$0.91 ▼ $3.23	$299.56M	2.52	2.47 million shs	3.39 million shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$75.07M	0.19	588,113 shs	293,835 shs
MYGN Myriad Genetics	$3.15 -0.6%	$5.05	$2.74 ▼ $8.59	$303.21M	1.69	2.18 million shs	3.71 million shs
SABS SAB Biotherapeutics	$3.77 -2.1%	$3.67	$1.85 ▼ $5.15	$294.39M	0.53	552,694 shs	284,285 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+1.17%	+10.17%	-13.04%	+7.00%	+140.74%
GANX Gain Therapeutics	+2.27%	+6.51%	-0.55%	-3.74%	+7.78%
MYGN Myriad Genetics	-0.63%	-37.50%	-47.76%	-22.98%	-18.60%
SABS SAB Biotherapeutics	-2.08%	+8.33%	-3.83%	-7.82%	+63.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.60 +1.2%	$2.48	$0.91 ▼ $3.23	$299.56M	2.52	2.47 million shs	3.39 million shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$75.07M	0.19	588,113 shs	293,835 shs
MYGN Myriad Genetics	$3.15 -0.6%	$5.05	$2.74 ▼ $8.59	$303.21M	1.69	2.18 million shs	3.71 million shs
SABS SAB Biotherapeutics	$3.77 -2.1%	$3.67	$1.85 ▼ $5.15	$294.39M	0.53	552,694 shs	284,285 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	+1.17%	+10.17%	-13.04%	+7.00%	+140.74%
GANX Gain Therapeutics	+2.27%	+6.51%	-0.55%	-3.74%	+7.78%
MYGN Myriad Genetics	-0.63%	-37.50%	-47.76%	-22.98%	-18.60%
SABS SAB Biotherapeutics	-2.08%	+8.33%	-3.83%	-7.82%	+63.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.29	Hold	$5.13	97.12% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	316.67% Upside
MYGN Myriad Genetics	2.00	Hold	$5.38	70.63% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	218.30% Upside

Current Analyst Ratings Breakdown

Latest GANX, FATE, SABS, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$5.50 ➝ $3.00
7/31/2026	MYGN Myriad Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$6.00 ➝ $4.00
7/30/2026	MYGN Myriad Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/14/2026	MYGN Myriad Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/24/2026	MYGN Myriad Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	SABS SAB Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
6/17/2026	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $16.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	45.57	N/A	N/A	$1.80 per share	1.44
GANX Gain Therapeutics	$50K	1,535.40	N/A	N/A	$0.48 per share	3.75
MYGN Myriad Genetics	$824.50M	0.37	$3.75 per share	0.84	$3.18 per share	0.99
SABS SAB Biotherapeutics	$1.32M	218.37	$0.33 per share	11.27	$3.18 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.09	N/A	N/A	N/A	-2,056.79%	-58.89%	-39.39%	8/11/2026 (Estimated)
GANX Gain Therapeutics	-$20.16M	-$0.58	N/A	N/A	N/A	N/A	-201.44%	-136.24%	8/6/2026 (Estimated)
MYGN Myriad Genetics	-$365.90M	-$1.19	N/A	N/A	N/A	-13.96%	-16.09%	-8.10%	N/A
SABS SAB Biotherapeutics	$13.27M	-$2.11	N/A	N/A	N/A	N/A	-0.29%	-0.25%	8/6/2026 (Estimated)

Latest GANX, FATE, SABS, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	FATE Fate Therapeutics	-$0.2682	N/A	N/A	N/A	$1.37 million	N/A
8/6/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	N/A	N/A	N/A	$0.03 million	N/A
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	N/A	N/A	N/A	$0.13 million	N/A
7/30/2026	Q2 2026	MYGN Myriad Genetics	-$0.0579	-$0.25	-$0.1921	-$0.46	$206.03 million	$190.70 million
5/13/2026	Q1 2026	FATE Fate Therapeutics	-$0.29	-$0.26	+$0.03	-$0.26	$1.49 million	$1.30 million
5/12/2026	Q1 2026	SABS SAB Biotherapeutics	-$0.20	-$0.35	-$0.15	-$0.35	$0.13 million	N/A
5/11/2026	Q1 2026	GANX Gain Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	5.85	5.85
GANX Gain Therapeutics	0.02	4.69	4.69
MYGN Myriad Genetics	0.40	2.21	1.98
SABS SAB Biotherapeutics	0.01	11.45	11.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
GANX Gain Therapeutics	11.97%
MYGN Myriad Genetics	99.02%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
GANX Gain Therapeutics	4.15%
MYGN Myriad Genetics	1.90%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	116.56 million	111.03 million	Optionable
GANX Gain Therapeutics	20	42.65 million	40.88 million	Optionable
MYGN Myriad Genetics	2,700	95.65 million	93.83 million	Optionable
SABS SAB Biotherapeutics	140	76.46 million	70.81 million	Not Optionable

GANX, FATE, SABS, and MYGN Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Takes Position in SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

Perceptive Advisors LLC Buys 5,628,533 Shares of SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

DV Trading LLC Takes $1.53 Million Position in SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Lowered by Wall Street Zen

August 2, 2026 | americanbankingnews.com

SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell

August 2, 2026 | marketbeat.com

SAB Biotherapeutics (SABS) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Affinity Asset Advisors LLC Invests $2.20 Million in SAB Biotherapeutics, Inc. $SABS

July 25, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Upgraded to "Sell" at Wall Street Zen

July 25, 2026 | marketbeat.com

Monashee Investment Management LLC Invests $1.92 Million in SAB Biotherapeutics, Inc. $SABS

July 23, 2026 | marketbeat.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 17, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6% - Still a Buy?

July 16, 2026 | marketbeat.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | globenewswire.com

Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 23, 2026 | msn.com

Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%

May 21, 2026 | aaii.comA

SAB Biotherapeutics Inc SABS

May 20, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, FATE, SABS, and MYGN Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.60 +0.03 (+1.17%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$2.58 -0.02 (-0.58%)

As of 04:01 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Gain Therapeutics NASDAQ:GANX

$1.80 +0.04 (+2.27%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.76 -0.04 (-2.22%)

As of 08/5/2026 07:54 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Myriad Genetics NASDAQ:MYGN

$3.15 -0.02 (-0.63%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.20 +0.05 (+1.62%)

As of 04:00 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

SAB Biotherapeutics NASDAQ:SABS

$3.77 -0.08 (-2.08%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.85 +0.08 (+2.23%)

As of 04:10 AM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GANX, FATE, SABS, and MYGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GANX, FATE, SABS, and MYGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GANX, FATE, SABS, and MYGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, FATE, SABS, and MYGN Company Descriptions

Fate Therapeutics NASDAQ:FATE

Gain Therapeutics NASDAQ:GANX

Myriad Genetics NASDAQ:MYGN

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GANX, FATE, SABS, and MYGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GANX, FATE, SABS, and MYGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GANX, FATE, SABS, and MYGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, FATE, SABS, and MYGN Company Descriptions

Fate Therapeutics NASDAQ:FATE

Gain Therapeutics NASDAQ:GANX

Myriad Genetics NASDAQ:MYGN

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools